Literature DB >> 3309074

Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B.

F Gigliotti1, J L Shenep, L Lott, D Thornton.   

Abstract

Amphotericin B produces chills and fever in a significant proportion of patients who receive this drug. The mechanism for this adverse effect is unknown. Amphotericin B suspension at a concentration of 1.0 microgram/ml was demonstrated to be a potent inducer of prostaglandin E2 synthesis by human and murine mononuclear cells in vitro. A double-blind, placebo-controlled clinical trial demonstrated that ibuprofen (10 mg/kg), a potent inhibitor of prostaglandin synthesis, administered 30 min before amphotericin B administration reduced the incidence of chilling from 87% to 49% (P = .01); the incidence of chilling reactions considered severe was reduced from 69% to 15% (P = .008). We postulate that the chills and fever produced by an infusion of amphotericin B are mediated through prostaglandin E2 synthesis. Ibuprofen is therapeutically useful in ameliorating the chills and fever caused by amphotericin B.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3309074     DOI: 10.1093/infdis/156.5.784

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

2.  Reduction of no synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers.

Authors:  M Larabi; P Legrand; M Appel; S Gil; M Lepoivre; J Devissaguet; F Puisieux; G Barratt
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 3.  Candidiasis.

Authors:  F Meunier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

Review 4.  Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?

Authors:  Daniela Baracaldo-Santamaría; Juan David Cala-Garcia; Germán José Medina-Rincón; Luis Carlos Rojas-Rodriguez; Carlos-Alberto Calderon-Ospina
Journal:  Antibiotics (Basel)       Date:  2022-05-12

5.  Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.

Authors:  P Y Chavanet; I Garry; N Charlier; D Caillot; J P Kisterman; M D'Athis; H Portier
Journal:  BMJ       Date:  1992-10-17

6.  Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B.

Authors:  D Caillot; P Chavanet; O Casasnovas; E Solary; G Zanetta; M Buisson; O Wagner; B Cuisenier; A Bonnin; P Camerlynck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

7.  Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells.

Authors:  J D Cleary; S W Chapman; R L Nolan
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

8.  Evaluation of in vitro and in vivo Efficacy of a Novel Amphotericin B-Loaded Nanostructured Lipid Carrier in the Treatment of Leishmania braziliensis Infection.

Authors:  Jéssica Rebouças-Silva; Maraine Catarina Tadini; Danielle Devequi-Nunes; Ana Luíza Mansur; Paulo S Silveira-Mattos; Camila I de Oliveira; Fábio R Formiga; Andresa A Berretta; Franciane Marquele-Oliveira; Valéria M Borges
Journal:  Int J Nanomedicine       Date:  2020-11-05

Review 9.  Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B.

Authors:  Jill Adler-Moore; Russell E Lewis; Roger J M Brüggemann; Bart J A Rijnders; Andreas H Groll; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

Review 10.  Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections.

Authors:  Francelise B Cavassin; João Luiz Baú-Carneiro; Rogério R Vilas-Boas; Flávio Queiroz-Telles
Journal:  Infect Dis Ther       Date:  2021-02-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.